Brochures Overview
The RIS method predicts in vivo CYP3A4 induction magnitude using in vitro data. It correlates a drug’s induction score (based on Emax, EC50, and unbound Cmax) to clinical AUC changes of midazolam via a calibration curve. Drugs with predicted ≥20% AUC reduction (AUCR ≤0.8) require follow-up (clinical DDI or modeling). Uses qualified hepatocytes and controls (rifampicin/flumazenil).
Complete the form to view and download this brochure.
Stay Connected
Keep up with the latest news and insights.